Develops drugs for neurodegenerative diseases.
Dec 2025Revenue $0.00/yrExpenses $555M/yr
No trendCash runway ≈ 1.6 years from Jun 2026
Figures by year
When will Denali Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $555M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $555M | −$555M |
| Dec 2024 | $0.00 | $487M | −$487M |
| Dec 2023 | $331M | $527M | −$197M |
| Dec 2022 | $108M | $449M | −$341M |
| Dec 2021 | $48.7M | $344M | −$296M |
| Dec 2020 | $336M | $273M | $62.7M |
| Dec 2019 | $26.7M | $240M | −$213M |
| Dec 2018 | $129M | $176M | −$46.4M |
| Dec 2017 | $0.00 | $90.1M | −$90.1M |
| Dec 2016 | $0.00 | $87.4M | −$87.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.